eFFECTOR Secures $50M Funding From Lincoln Park Capital


eFFECTOR Therapeutics Inc EFTR entered into an investment agreement with Lincoln Park Capital for up to $50 million over 36 months.

  • The Company said a new group was added to evaluate frontline maintenance in patients with PD-L1 ≥1% in the Phase 2b KICKSTART trial of tomivosertib combined with Merck & Co Inc's MRK Keytruda (pembrolizumab) for non-small cell lung cancer (NSCLC).
  • This cohort will enroll approximately 60 patients.
  • Topline data from the ongoing frontline cohort in patients with PD-L1>50% and the new frontline maintenance cohort in patients with PD-L1>1% in the KICKSTART trial are now expected in H1 2023.
  • eFFECTOR also said it was discontinuing the development of tomivosertib in patients who have already progressed on pembrolizumab monotherapy.
  • In addition, first patients have been dosed in two additional Phase 2 expansion cohorts evaluating zotatifin in combination with sotorasib in KRAS G12C-mutant NSCLC and combination with abemaciclib and fulvestrant in ER+/HER2- breast cancer.
  • Related: eFFECTOR Therapeutics Stock Gains On Encouraging Preclinical Zotatifin Data In Breast Cancer.
  • eFFECTOR anticipates initial response data from one or more of the expansion cohorts, and additional data from the Phase 1 dose-escalation portion of the trial, in 1H of 2022. 
  • It anticipates topline results from the trial in 2H of 2022.
  • Price Action: EFTR shares closed 4.21% lower at $6.04 during after-hours trading on Monday. 
Market News and Data brought to you by Benzinga APIs
Posted In: BiotechNewsHealth CareFinancingMoversTrading IdeasGeneralBriefs
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!